TY - JOUR
T1 - Mitigating Implicit Bias in Radiation Oncology
AU - Diaz, Dayssy Alexandra
AU - Suneja, Gita
AU - Jagsi, Reshma
AU - Barry, Parul
AU - Thomas, Charles R.
AU - Deville, Curtiland
AU - Winkfield, Karen
AU - Siker, Malika
AU - Bott-Kothari, Terri
N1 - Funding Information:
Sources of support: This work had no specific funding. Disclosures: G.S. is supported by funding from the National Cancer Institute/National Institutes of Health. R.J. has Equity Quotient stock options and has received personal fees from Amgen and Vizient and grants from NCI, The Doris Duke Charitable Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium. She has a contract to conduct an investigator initiated study with Genentech. Expert witness: Sherinian and Hasso and Dressman Benzinger LaVelle. She is also an uncompensated founding member of TIME'S UP Healthcare and a member of the board of directors of ASCO. K.W. has received personal fees from Pfizer, Merck, Grail Bio, and Bristol-Myers Squibb. P.B. has received an ACRO new practitioner seed grant, Oslear board review course honoraria for board review, ACRO nonfinancial support, ASTRO, Franciscan Health System, and SANTRO honoraria for talk.
Funding Information:
Disclosures: G.S. is supported by funding from the National Cancer Institute/National Institutes of Health. R.J. has Equity Quotient stock options and has received personal fees from Amgen and Vizient and grants from NCI, The Doris Duke Charitable Foundation, the Greenwall Foundation, the Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium. She has a contract to conduct an investigator initiated study with Genentech. Expert witness: Sherinian and Hasso and Dressman Benzinger LaVelle. She is also an uncompensated founding member of TIME'S UP Healthcare and a member of the board of directors of ASCO. K.W. has received personal fees from Pfizer, Merck, Grail Bio, and Bristol-Myers Squibb. P.B. has received an ACRO new practitioner seed grant, Oslear board review course honoraria for board review, ACRO nonfinancial support, ASTRO, Franciscan Health System, and SANTRO honoraria for talk.
Publisher Copyright:
© 2021 The Author(s)
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Implicit bias is one of the most insidious and least recognizable mechanisms that can cause inequity and disparities. There is increasing evidence that both implicit and explicit biases have a negative effect on patient outcomes and patient-physician relationships. Given the impact of Implicit bias, a joint session between ASTROs Committee on Health Equity, Diversity, and Inclusion and the National Cancer Institute (the ASTRO-National Cancer Institute Diversity Symposium) was held during the American Society of Radiation Oncology (ASTRO) 2020 Annual Meeting, to address the effect of implicit bias in radiation oncology through real life and synthesized hypothetical scenario discussions. Given the value of this session to the radiation oncology community, the scenarios and discussion are summarized in this manuscript. Our goal is to heighten awareness of the multiple settings in which implicit bias can occur as well as discuss resources to address bias.
AB - Implicit bias is one of the most insidious and least recognizable mechanisms that can cause inequity and disparities. There is increasing evidence that both implicit and explicit biases have a negative effect on patient outcomes and patient-physician relationships. Given the impact of Implicit bias, a joint session between ASTROs Committee on Health Equity, Diversity, and Inclusion and the National Cancer Institute (the ASTRO-National Cancer Institute Diversity Symposium) was held during the American Society of Radiation Oncology (ASTRO) 2020 Annual Meeting, to address the effect of implicit bias in radiation oncology through real life and synthesized hypothetical scenario discussions. Given the value of this session to the radiation oncology community, the scenarios and discussion are summarized in this manuscript. Our goal is to heighten awareness of the multiple settings in which implicit bias can occur as well as discuss resources to address bias.
UR - http://www.scopus.com/inward/record.url?scp=85111316849&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111316849&partnerID=8YFLogxK
U2 - 10.1016/j.adro.2021.100738
DO - 10.1016/j.adro.2021.100738
M3 - Article
AN - SCOPUS:85111316849
VL - 6
JO - Advances in Radiation Oncology
JF - Advances in Radiation Oncology
SN - 2452-1094
IS - 5
M1 - 100738
ER -